Assessment of Platelet-derived GARP in Atherosclerotic Disease

Starting soon

Conditions studied: Atheroma; Carotid Artery, Atheromatosis

In brief

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Key facts

Study ID
NCT07364058
Run by
Université Catholique de Louvain
People needed
200
Starts
2026-02-01
Expected to finish
2029-01-01
Last updated by the study team
2026-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.